Eight top papers showcase scientific progress in multiple sclerosis research in 2014

The U.S. Agency for Healthcare Research and Quality (AHRQ) recently released a draft review on the evidence on discontinuation of disease-modifying therapies. Shocked by the apparent lack of expertise in the first draft, MS researchers and advocacy groups sent in a wave of comments chastising the AHRQ for the perceived shoddiness of the report.

The risk of relapse is higher in the postpartum period, but there are conflicting suggestions for women with MS about reducing this risk. Can exclusive breastfeeding alone prevent relapses? How soon after delivery should DMTs be reintroduced? Are any DMTs safe to take while breastfeeding?

Phase 3 results show that daclizumab reduces disease activity in relapsing-remitting multiple sclerosis by half compared with interferon, as measured by brain imaging, with skin and other side effects. The drug works in surprising ways that are revealing new details about the pathogenesis of MS.